Lithium Carbonate in the Treatment of Graves’ Disease with ATD-Induced Hepatic Injury or Leukopenia

Table 3

Factors associated with the outcome of hyperthyroidism.

	OR	95% CI
Age	0.867	0.924–1.382	0.651
Course of GD	4.080	1.108–15.020	0.034
Gender (male/female)	0.189	0.014–1.473	0.091
Serum FT3 at baseline	0.049	0.006–0.431	0.007
Serum FT4 at baseline	0.031	0.027–0.642	0.015
Serum TSH at baseline	0.246	0.023–2.163	0.249
Serum FT3 at 36 weeks	0.039	0.003–0.453	0.010
Serum FT4 at 36 weeks	0.055	0.004–0.960	0.047
Serum TSH at 36 weeks	0.099	0.008–1.288	0.077
Positive TRAb	0.032	0.003–0.433	0.009
Positive TPOAb	0.139	0.012–1.684	0.121
Positive TGAb	0.179	0.015–2.140	0.174
Lithium dose	0.212	0.018–2.467	0.215
Serum lithium concentration	0.324	0.036–1.539	0.387
Propranolol	0.287	0.025–1.283	0.264
Thyromegaly	0.022	0.016–0.352	0.013

FT4, free thyroxine; FT3, free triiodothyronine; TSH, thyroid stimulating hormone; TRAb, thyrotropin receptor antibody; TgAb, thyroglobulin antibodies; TPOAb, thyroglobulin antibodies.